0000899243-23-011945.txt : 20230501 0000899243-23-011945.hdr.sgml : 20230501 20230501164625 ACCESSION NUMBER: 0000899243-23-011945 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230427 FILED AS OF DATE: 20230501 DATE AS OF CHANGE: 20230501 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ege David S. CENTRAL INDEX KEY: 0001829360 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 23874503 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-27 0 0001609809 Seres Therapeutics, Inc. MCRB 0001829360 Ege David S. C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks 0 Common stock 2023-04-27 4 A 0 20000 0.00 A 66734 D Common stock 2023-04-28 4 S 0 7038 5.19 D 59696 D On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 20,000 shares. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 3, 2021, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0350 to $5.1900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Executive Vice President and Chief Technology Officer /s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege 2023-05-01